Affiliation: National Institutes of Health
- Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusionIdoya Lahortiga
Human Genome Laboratory, Department of Molecular and Developmental Genetics, VIB, Leuven, Belgium
Haematologica 93:49-56. 2008..We report an unusual case of a patient presenting with peripheral basophilia and systemic mastocytosis in whom cytogenetic analysis revealed a t(4;5)(q21.1;q31.3)...
- Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndromeJamie Robyn
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
Br J Haematol 132:286-92. 2006..These results suggest that the mutation arises in a pluripotential haematopoietic progenitor cell capable of giving rise to multiple lineages. The basis for the preferential expansion of eosinophils and mast cells remains unclear...
- Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingAmy D Klion
Laboratory of Parasitic Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health NIH, Bethesda, MD 20892, USA
Blood 110:3552-6. 2007..This trial was registered at http://www.clinicaltrials.gov as no. NCT00044304...
- KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entitiesIrina Maric
Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
J Allergy Clin Immunol 120:680-7. 2007..It is of paramount importance, however, to distinguish between these 2 groups of patients because of differences in clinical sequelae, prognoses, and selection of treatment...
- Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosisTodd M Wilson
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 1881, USA
Haematologica 96:459-63. 2011..Unlike other mature lineages, mast cell survival is dependent on KIT and the presence of these two activating mutations may have a greater impact on the expansion of this cell compartment and in resultant disease severity...
- Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeAmy D Klion
Bldg 4, Rm 126, National Institutes of Health, Bethesda, MD 20892
Blood 103:473-8. 2004..The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES...
- Imatinib-responsive hypereosinophilia in a patient with B cell ALLJamie Robyn
Hematology Branch, National Heart Lung and Blood Institute National Institutes of Health Bethesda, MD 20892, USA
Leuk Lymphoma 45:2497-501. 2004..He was subsequently diagnosed with CD10 positive precursor B lymphoblastic leukemia. This case underscores the importance of follow-up bone marrow examination in patients who demonstrate imatinib mesylate-responsive eosinophilia...
- Treatment of systemic mastocytosisTodd M Wilson
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11C205, 10 Center Drive, MSC 1881, Bethesda, MD 20892, USA
Immunol Allergy Clin North Am 26:549-73. 2006..This has directly translated into the development of novel targeted therapies. These therapies hold great promise to patients and health care providers that a "cure" for systemic mastocytosis may someday be obtainable...
- Imatinib-responsive hypereosinophilic syndromeJamie Robyn
Leuk Res 30:915-6. 2006